Day: March 19, 2026

Nashville, TN, March 19, 2026 (GLOBE NEWSWIRE) — American Rebel Holdings, Inc. (NASDAQ: AREB) — America’s Patriotic Brand (the “Company”), today announced that it will effect a reverse stock split of its outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), and publicly traded warrants, par value $0.001 per share (the “Warrants”), at a ratio of 1-for-100, to be effective on March 23, 2026. The Company’s Common Stock and Warrants are scheduled to begin trading on a reverse stock split-adjusted basis at the opening of Nasdaq on Monday, March 23, 2026. Following the reverse stock split, the Common Stock will continue to trade on Nasdaq under the symbol “AREB” with a new CUSIP number 02919L 885 and the Warrants will continue to trade on Nasdaq under the symbol “AREBW” with a same CUSIP number of 02919L...

TORONTO, March 19, 2026 (GLOBE NEWSWIRE) — Equifax® Canada, a global data, analytics, and technology company, today announced that it is now offering Equifax customers access to ReadyResponse from Breachlink, a leading provider of data breach preparedness, coordination, and incident management. This comprehensive service helps small and mid-sized businesses (SMBs) prepare for, respond to, and recover from cybersecurity incidents, equipping businesses with the roadmap and connections to effectively respond. ReadyResponse combines essential readiness resources, specialized legal expertise, and discounted rates to a curated network of breach response professionals, helping organizations act swiftly and confidently when a cyber incident occurs. “At Equifax, continuing to be a leader in cybersecurity is a strategic business priority,...

BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc. (Nasdaq: ACON, ACONW) (“Aclarion” or the “Company”) today announced that its Board of Directors (the “Board”) has unanimously adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to make informed decisions that are in the best interest of Aclarion and its stockholders. The Rights Plan applies equally to all current and future...

Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) — Biofrontera Inc. (NASDAQ:BFRI) (the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial HighlightsRevenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024. Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in 4Q24, reflecting the transition away from the transfer pricing model under the prior license and supply agreement. Operating income was $4.6 million in 4Q25 compared...

Appointment of Joseph Tenne Adds Public Company Leadership as Gauzy Advances Growth and Shareholder Value TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a global leader in vision and light control technologies, today announced the appointment of Joseph Tenne to its Board of Directors. Mr. Tenne brings more than two decades of senior financial leadership and public company governance experience across global technology and energy companies. Mr. Tenne will also serve as the Chair of the Company’s audit committee and as a member of the compensation committee. With this appointment, and together with the recent additions of Michael Martin, Shlomo Bibas and Renah Persofsky to the Board, Gauzy has regained compliance with Nasdaq’s continued listing requirements related to board...

– Purchase commitment is for a minimum of $1.475 million of Symvess product – DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has received a minimum purchase commitment of $1.475 million of the Symvess acellular tissue engineered vessel to facilitate a clinical evaluation and outreach program in hospitals within the Kingdom of Saudi Arabia (KSA). The planned clinical evaluation program is to be conducted in parallel with ongoing negotiations with a KSA-based entity for establishment of a joint venture and license to commercialize Symvess within the country. Humacyte will provide personnel to train medical professionals in the use...

Vancouver, Canada, March 19, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful continuation of treatment of participants in the third cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This positive progress follows the Company’s recent announcement on March 11, 2026, regarding the advancement of participant enrollment for the third cohort at Yale University, Johns Hopkins University, and...

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing devices for workplace safety and law enforcement, is pleased to announce the first commercial sales of its Marijuana Breath Test (“MBT”) products into the construction industry. The products were sold to a major construction company located in the Pacific Northwest through an authorized reseller. The client—a large regional contractor engaged in industrial, civil, and commercial construction—sought a next-generation solution to strengthen workplace safety protocols by accurately assessing recent cannabis use among its workforce. A Critical Solution for Safety-Sensitive Industries The construction sector faces one of the...